Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus... Infection (2017) 45:521–528 DOI 10.1007/s15010-017-1018-z ORIGINAL PAPER Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV‑infected patients with HIV‑1 RNA ≤50 cp/mL 1 2 3 4 Giordano Madeddu · Stefano Rusconi · Alessandro Cozzi‑Lepri · Simona Di Giambenedetto · 5 6 7 6 8 9 Stefano Bonora · Alessia Carbone · Andrea De Luca · Nicola Gianotti · Antonio Di Biagio · Andrea Antinori · for the Icona Foundation Study Group Received: 14 November 2016 / Accepted: 13 April 2017 / Published online: 5 May 2017 © Springer-Verlag Berlin Heidelberg 2017 Abstract raltegravir (RAL) while having a viral load (VL) ≤50 cop- Background Nucleos(t)ide reverse transcriptase inhibitors ies/mL in the clinical setting. (NRTI) toxicity may represent a threat for long-term suc- Study design Treatment-experienced HIV 1-infected cess of combined antiretroviral therapy. Some studies have patients enrolled in the ICONA Foundation Study cohort suggested a possible improvement of NRTI-related toxicity were included if they switched their current regimen to after switching to NRTI-sparing regimens. DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Differ- Objectives We aimed to explore the efficacy and toler - ent definitions of virological failure (VF) and treatment ability of switching http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infection Springer Journals

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL

Loading next page...
 
/lp/springer-journals/efficacy-and-tolerability-of-switching-to-a-dual-therapy-with-INm1sZnRMa

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Infectious Diseases; General Practice / Family Medicine; Internal Medicine
ISSN
0300-8126
eISSN
1439-0973
DOI
10.1007/s15010-017-1018-z
pmid
28477212
Publisher site
See Article on Publisher Site

Abstract

Infection (2017) 45:521–528 DOI 10.1007/s15010-017-1018-z ORIGINAL PAPER Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV‑infected patients with HIV‑1 RNA ≤50 cp/mL 1 2 3 4 Giordano Madeddu · Stefano Rusconi · Alessandro Cozzi‑Lepri · Simona Di Giambenedetto · 5 6 7 6 8 9 Stefano Bonora · Alessia Carbone · Andrea De Luca · Nicola Gianotti · Antonio Di Biagio · Andrea Antinori · for the Icona Foundation Study Group Received: 14 November 2016 / Accepted: 13 April 2017 / Published online: 5 May 2017 © Springer-Verlag Berlin Heidelberg 2017 Abstract raltegravir (RAL) while having a viral load (VL) ≤50 cop- Background Nucleos(t)ide reverse transcriptase inhibitors ies/mL in the clinical setting. (NRTI) toxicity may represent a threat for long-term suc- Study design Treatment-experienced HIV 1-infected cess of combined antiretroviral therapy. Some studies have patients enrolled in the ICONA Foundation Study cohort suggested a possible improvement of NRTI-related toxicity were included if they switched their current regimen to after switching to NRTI-sparing regimens. DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Differ- Objectives We aimed to explore the efficacy and toler - ent definitions of virological failure (VF) and treatment ability of switching

Journal

InfectionSpringer Journals

Published: May 5, 2017

There are no references for this article.